Absorbed doses in humans from  188 Re-Rituximab in the free form and bound to superparamagnetic iron oxide nanoparticles: Biodistribution study in mice

Azadbakht, Bakhtiar; Afarideh, H.; Ghannadi‐Maragheh, Mohammad; Bahrami-Samani, Ali; Yousefnia, Hassan

doi:10.1016/j.apradiso.2017.10.041

Cited by 12 publications

(10 citation statements)

References 29 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In another seminal study, 89 Zr‐ferumoxytol‐desferrioxamine chelate radiolabelled iron oxide nanoparticles have shown appreciable potential for deep tissue lymphatic drainage imaging as an indicator of cancer prognosis and therapeutic monitoring 72 . The iron oxide nanoparticle platform has proved particularly useful for a wide range of radionuclides like 166 Ho, 177 Lu, 188 Re, and 223 Ra 73–76 …”

Section: Different Nanoparticle Systems Used For Delivery Of Radiophamentioning

confidence: 99%

Nanoparticulate formulations of radiopharmaceuticals: Strategy to improve targeting and biodistribution properties

Datta

Ray

2020

Labelled Comp Radiopharmac

View full text Add to dashboard Cite

Application of nanotechnology principles in drug delivery has created opportunities for treatment of several diseases. Nanotechnology offers the advantage of overcoming the adverse biopharmaceutics or pharmacokinetic properties of drug molecules, to be determined by the transport properties of the particles themselves. Through the manipulation of size, shape, charge, and type of nanoparticle delivery system, variety of distribution profiles may be obtained. However, there still exists greater need to derive and standardize definitive structure property relationships for the distribution profiles of the delivery system. When applied to radiopharmaceuticals, the delivery systems assume greater significance. For the safety and efficacy of both diagnostics and therapeutic radiopharmaceuticals, selective localization in target tissue is even more important. At the same time, the synthesis and fabrication reactions of radiolabelled nanoparticles need to be completed in much shorter time. Moreover, the extensive understanding of the several interesting optical and magnetic properties of materials in nanoscale provides for achieving multiple objectives in nuclear medicine. This review discusses the various nanoparticle systems, which are applied for radionuclides and analyses the important bottlenecks that are required to be overcome for their more widespread clinical adaptation.

show abstract

Section: Different Nanoparticle Systems Used For Delivery Of Radiophamentioning

confidence: 99%

Nanoparticulate formulations of radiopharmaceuticals: Strategy to improve targeting and biodistribution properties

Datta

Ray

2020

Labelled Comp Radiopharmac

View full text Add to dashboard Cite

show abstract

“…Absorbed doses to human organs from 188 Re‐rituximab in the free form and bound to superparamagnetic NPs were predicted from results of the radiopharmaceutical biodistribution studies in mice by the RADAR method. Azadbakht et al reported that equivalent and effective doses to human organs from the radiopharmaceutical on the NPs are higher because of the EPR effect. Liver, spleen, and kidneys received higher equivalent doses than other organs.…”

Section: Radiolabeled Nanocarriers For Nuclear Molecular Imaging and mentioning

confidence: 99%

An overview of nanoscale radionuclides and radiolabeled nanomaterials commonly used for nuclear molecular imaging and therapeutic functions

Farzin¹,

Sheibani²,

Moassesi³

et al. 2018

J Biomedical Materials Res

View full text Add to dashboard Cite

show abstract

“…In another publication 223 Ra-doped BaFe nanoparticles were presented as candidates for multimodal drug combining localized magnetic hyperthermia with internal α-therapy [4]. Magnetic nanoparticles labeled also with βemitters ( 188 Re, 198 Au, 90 Y, and 131 I) and Auger electrons emitters ( 111 In, 125 I) were also investigated, some of them in preclinical studies [5][6][7][8][9].…”

Section: Introductionmentioning

confidence: 99%

“…In medical applications, MNPs can be coated with a biocompatible polymer to increase stability and bioavailability [11] or coated with antibody for biomarker immobilization [12]. Among others, MNPs modified with Hyperbranched Polyglycerol (HPG) have attracted much attention for years [1][2][3][4][5][6][7][8][9][10][11][13][14][15]. Having three-dimensional structures and numerous internal and external functional groups, these compounds can serve as remarkable hosts for metal complexes, enzymes, and biomaterials.…”

Section: Introductionmentioning

confidence: 99%

Multimodal Radiobioconjugates of Magnetic Nanoparticles Labeled with <sup>44</sup>Sc and <sup>47</sup>Sc for Theranostic Application

Ünak¹,

Yasakçı²,

Tutun³

et al. 2023

Preprint

View full text Add to dashboard Cite

This study was performed to synthesize multimodal radiopharmaceutical designed for the diagnosis and treatment of prostate cancer. To achieve this goal, Super Paramagnetic Iron Oxide (SPIO) nanoparticles were used as a platform for targeting molecule (PSMA-617) and for complexation of two scandium radionuclides, 44Sc for PET imaging and 47Sc for radionuclide therapy. TEM and XPS images showed that the Fe3O4 NPs have a uniform cubic shape and a diameter from 38 to 50 nm. The Fe3O4 core are surrounded by SiO2 and an organic layer. The saturation magnetization of the SPION core was 60 emu/g. However, coating the SPIONs with silica and polyglycerol reduces the magnetization significantly. The obtained bioconjugates were labeled with 44Sc and 47Sc, with a yield higher than 97%. The radiobioconjugate exhibited high affinity and cytotoxicity towards the human prostate cancer LNCaP (PSMA+) cell line, much higher than for PC-3 (PSMA-) cells. High cytotoxicity of the radiobioconjugate was confirmed by radiotoxicity studies on LNCaP 3D-spheroids. In addition, the magnetic properties of the radiobioconjugate should allow for its use in guide drug delivery driven by magnetic field gradient.

show abstract

Absorbed doses in humans from 188 Re-Rituximab in the free form and bound to superparamagnetic iron oxide nanoparticles: Biodistribution study in mice

Cited by 12 publications

References 29 publications

Nanoparticulate formulations of radiopharmaceuticals: Strategy to improve targeting and biodistribution properties

Nanoparticulate formulations of radiopharmaceuticals: Strategy to improve targeting and biodistribution properties

An overview of nanoscale radionuclides and radiolabeled nanomaterials commonly used for nuclear molecular imaging and therapeutic functions

Multimodal Radiobioconjugates of Magnetic Nanoparticles Labeled with <sup>44</sup>Sc and <sup>47</sup>Sc for Theranostic Application

Contact Info

Product

Resources

About